| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 3867894 | The Journal of Urology | 2012 | 8 Pages |
Abstract
High dose rate brachytherapy as monotherapy is safe and effective for patients with intermediate risk prostate cancer. We recommend caution for percent positive biopsy cores exceeding 75% or clinical stage T2c. Excluding such patients the 5-year biochemical disease-free survival rate was 97.5%.
Keywords
PSAbDFSI-PSSIIEF-5PSBRTOGBRFsPermanent seed brachytherapyPBCTRUSHDREBRTProstate specific antigenBrachytherapybiochemical disease-free survivalBiochemical recurrence-free survivalRadical prostatectomySPIRITTransrectal ultrasoundInternational Index of Erectile FunctionNeoplasm stagingMortalityHigh dose rateProstatic neoplasmsInternational Prostate Symptom Scoreexternal beam radiation therapyProstateRadiation Therapy Oncology Group
Related Topics
Health Sciences
Medicine and Dentistry
Nephrology
Authors
C. Leland Rogers, Stephen C. Alder, R. LeGrand Rogers, Scott A. Hopkins, McKay L. Platt, Lane C. Childs, Ronald H. Crouch, Roger S. Hansen, John K. Hayes,